AAA
MIST icon

Affinity Asset Advisors’s Milestone Pharmaceuticals MIST Stock Holding History

Affinity Asset Advisors’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-137,200
Closed -$1.26M – 74
2022
Q3 		$1.26M Buy
+137,200
New +$1.04M 0.35% 48

Other funds holding MIST

PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Affinity Asset Advisors's MIST Position: Q4 2025 in Review

Affinity Asset Advisors sold out of Milestone Pharmaceuticals (MIST) in Q4 2025, closing a stake of 666,666 shares — an estimated $1.33M sold.

Affinity Asset Advisors first reported a position in MIST in Q4 2022 and held it in 5 quarters. The position peaked at $1.33M in Q3 2025. 79 funds tracked by Wall St. Rank hold MIST as of Q4 2025.

  • Affinity Asset Advisors reported no remaining Milestone Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 666,666 Milestone Pharmaceuticals shares in Q4 2025, an estimated $1.33M.
  • Affinity Asset Advisors first reported a position in Milestone Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • Affinity Asset Advisors's Milestone Pharmaceuticals position peaked at $1.33M in Q3 2025.
  • 79 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q4 2025.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.